Loading...
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter, J Ribas, A Long, G Arance, A Grob, J Mortier, L Daud, A Carlino, M McNeil, C Lotem, M
Schachter, J
Ribas, A
Long, G
Arance, A
Grob, J
Mortier, L
Daud, A
Carlino, M
McNeil, C
Lotem, M
Citations
Altmetric:
Abstract
Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis.
Description
Date
2017-08-16
Publisher
Collections
Keywords
Type
Article
Citation
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). 2017 Lancet